Targeted therapies for HER2+ breast cancer include monoclonal antibodies such as trastuzumab and pertuzumab, which prevent receptor dimerization and signaling, and tyrosine kinase inhibitors like lapatinib and neratinib that inhibit the kinase activity of the HER2 receptor [7]. Here, ERBB2 is linked to breast cancer.